Medicine will evolve to a cost-efficient, personalized, predictive and preventive medicine supported by high-tech non-invasive tests detecting biomarkers and weak signals from body fluids."

Patrizia Paterlini-Bréchot

THE COMPANY



MISSION

Disrupt today’s cancer patient care toward personalized medicine and earlier detection of the disease for the benefit of people’s life, through an increased understanding of circulating tumor cells biology and the delivery of non-invasive powerful diagnostic tools based on rare circulating information in blood.

RARECELLS DIAGNOSTICS

Worldwide, about 18.1 million new cancers were diagnosed and 9.6 million people died of the disease. Therefore, finding an effective, non-invasive way to diagnose cancers accurately and earlier has the potential to save millions of lives each year.

The global liquid biopsy market was estimated at EUR 8.2 billion in 2017 with an expected growth to EUR 24.9 billion by 2023.

At Rarecells Diagnostics, we focused on the most critical healthcare unmet needs : the early detection of cancers. Delivering to caregivers the unique possibility to identify the presence of circulating cancer cells up to 4-5 years in advance of traditional imaging techniques and/or clinical symptoms.

We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET® (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor Cells, for the diagnosis of multiple cancer types and personalized therapeutic.

The company was founded in 2011 by Patrizia Paterlini-Bréchot, an Italian-French Woman, Onco-Hematologist, Prof. of Cellular and Molecular Biology at the University Paris Descartes (France) and inventor of the ISET® technology.

Rarecells Diagnostics is a spin-off of the French Public Institutions : Université Paris Descartes, INSERM (Institut National de la Santé et de la Recherche Médicale) and AP-HP (Assistance Publique- Hôpitaux de Paris) which own the ISET® patents. Rarecells Diagnostics has the exclusive licenses of the ISET® patents.

MANAGEMENT BOARD



Thierry Baglan
CEO
Thierry Baglan builds on a 10-year leadership experience as Director France at the Greater Geneva Berne Area Economic development Agency and 8 years at Economic Advancement Dews France,President of the FRAC training group (60 employees) from 1997 to 2001 . Former Regional Director of Bank Sofirec for 15 years, Bank Rothschild Subsidiary acquired by GE Capital. Graduated from Sciences-Po Aix-en-Provence.

Davide Bréchot
Deputy CEO
Davide Béchot has been focusing on the expansion of the operations and the development of service activities when he joint Rarecells Diagnostics. In charge of product development, he  designed a new generation of ISET product, as well as overseeing regulatory compliance for the group In 2013. Previously COO for Rarecells Holding, he was also the co-founder of a start-up in the digital space in the food tech sector, for which he served as President and CTO. Davide holds a Master of Engineering from Imperial College London in Mechanical and Nuclear engineering, a Master of International Affairs from Sciences-Po Paris and a second Master of International Affairs from Columbia University.

Sébastien Dutoya
Chief Opérating Officer
Sébastien Dutoya joined Rarecells Diagnostics, at the end of 2018 as COO, to support the development of Rarecells Diagnostics. He is leveraging his former industrial international managerial positons and corporate internal auditor function at Vallourec, a multinational company specialized in steel tubes mainly for energy industry. Sébastien is an expert in change management, continuous improvement and Internal audit. He has an Engineering degree from École Centrale Paris, France.

Franck Parazza
Director of Marketing and Sales
Franck Parazza joined Rarecells in 2019 to drive the business development effort and to structure the marketing department of the company. Formerly Marketing leader women’s health & cancers, European business unit director cervical cancer (Becton Dickinson) and Intl Product manager IVD (AutoCytes), Franck is bringing a strong IVD experience of international sales and marketing into Rarecells. PhD in biomedical engineering, MBA.


Thierry Baglan
CEO
Thierry Baglan builds on a 10-year leadership experience as Director France at the Greater Geneva Berne Area Economic development Agency and 8 years at Economic Advancement Dews France,President of the FRAC training group (60 employees) from 1997 to 2001 . Former Regional Director of Bank Sofirec for 15 years, Bank Rothschild Subsidiary acquired by GE Capital. Graduated from Sciences-Po Aix-en-Provence.

Davide Bréchot
Deputy CEO
Davide Béchot has been focusing on the expansion of the operations and the development of service activities when he joint Rarecells Diagnostics. In charge of product development, he  designed a new generation of ISET® product, as well as overseeing regulatory compliance for the group In 2013. Previously COO for Rarecells Holding, he was also the co-founder of a start-up in the digital space in the food tech sector, for which he served as President and CTO. Davide holds a Master of Engineering from Imperial College London in Mechanical and Nuclear engineering, a Master of International Affairs from Sciences-Po Paris and a second Master of International Affairs from Columbia University.

Sébastien Dutoya
Chief Opérating Officer
Sébastien Dutoya joined Rarecells Diagnostics, at the end of 2018 as COO, to support the development of Rarecells Diagnostics. He is leveraging his former industrial international managerial positons and corporate internal auditor function at Vallourec, a multinational company specialized in steel tubes mainly for energy industry. Sébastien is an expert in change management, continuous improvement and Internal audit. He has an Engineering degree from École Centrale Paris, France.

Franck Parazza
Director of Marketing and Sales
Franck Parazza joined Rarecells in 2019 to drive the business development effort and to structure the marketing department of the company. Formerly Marketing leader women’s health & cancers, European business unit director cervical cancer (Becton Dickinson) and Intl Product manager IVD (AutoCytes), Franck is bringing a strong IVD experience of international sales and marketing into Rarecells. PhD in biomedical engineering, MBA.

SCIENTIFIC ADVISORY BOARD



Patrizia Paterlini-Bréchot
MD, PhD and founder of Rarecells
Professor of Cell biology and Oncology, Director at INSERM, Patrizia Paterlini-Bréchot is the founder of Rarecells SAS and Rarecells USA, Inc. In addition to fundamental research studies early in her career, she focused on applied research, targeting the domains of predictive oncology and prenatal diagnosis.

In 2000, her research led to the discovery and development of the now patented ISET® technique for isolation and characterization of circulating tumor and fetal cells permitting predictive oncology and non invasive prenatal diagnosis. Prof Paterlini-Bréchot oversees the continuing development of the ISET® technology. Her work was acknowledged by numerous awards and led to high level scientific publications.

Dr. Hood Leroy
M.D., Johns Hopkins School of Medicine
Ph.D., Biochemistry, California Institute of Technology
Dr. Hood’s research has focused on the study of molecular immunology, biotechnology, and genomics.  He won the 2003 Lemelson-MIT Prize for inventing “four instruments that have unlocked much of the mystery of human biology” by helping decode the genome. His inventions include the DNA sequencer that contributed to the successful mapping of the human genome.

His professional career began at Caltech where he and his colleagues pioneered four instruments, which comprise the technological foundation for contemporary molecular biology. In 1992, Dr. Hood moved to the University of Washington as founder and Chairman of the cross-disciplinary Department of Molecular Biotechnology.

Joe Leigh Simpson
MD – Chair and Professor
Professor of Obstetrics and Gynecology
Professor of Human and Molecular Genetics
Dr Simpson is the founding Chair at Florida International University Miami, and has served as Chair and Professor in numerous universities in the USA. Besides, he has played leadership roles in many professional organizations. His research encompasses many areas of genetic prenatal diagnosis and reproductive genetics.

He was 1993-1994 President of the American Society for Reproductive Medicine, 1994-1998 President of the International Society of Prenatal Diagnosis, 1998-1999 President of the Society for Gynecologic Investigation, 2007-09 President of the American College of Medical Genetics, 2006-09 President of the Preimplantation Genetic Diagnosis International Society He is a member of the National Academy of Sciences, Institute of Medicine (IOM).

Frank Anthony Greco
MD
Dr. Tony Greco is board certified in Medical Oncology and Internal Medicine. He has been with Tennessee Oncology since 1993. Dr. Greco specializes in cancers of unknown primary, lung cancer, and germ cell tumors. Dr. Greco holds memberships in the American Society of Clinical Oncology and the Southern Association of Oncology.

He is also a clinical researcher and director of Sarah Cannon Cancer Center and co-director of the Minnie Pearl Research Network. Dr. Greco comes to us from Vanderbilt University Medical Center, where he served as the Director of Medical Oncology and the Cancer Center.

Jean-Yves Blay
MD, PhD
Dr. Jean-Yves Blay is Professor of Medicine at the Université Claude Bernard in Lyon, France, and the Scientific Director of the Canceropole Lyon Rhône Alpes, a network of more than 1500 researchers and physicians working in the field of cancer. He is President of the Executive Committee of the EORTC (European Organization for the Research and Treatment of Cancer), Chairman of the French Sarcoma Group, and Director in the Conticanet Network (Conticanet.eu), a Network of excellence funded by the 6th FrameWork Program of the European Commission.

His research interests focus on clinical and basic research in sarcomas, the biology of breast carcinoma and relation between tumor microenvironment and malignant cells. Dr. Blay is an active member of the European Society of Medical Oncology, the American Society of Clinical Oncology and the American Association of Cancer Research. Dr. Blay serves as scientific committee board member of five Cancer Centers in France.

Patrizia Paterlini-Bréchot
MD, PhD and founder of Rarecells
Professor of Cell biology and Oncology, Director at INSERM, Patrizia Paterlini-Bréchot is the founder of Rarecells SAS and Rarecells USA, Inc. In addition to fundamental research studies early in her career, she focused on applied research, targeting the domains of predictive oncology and prenatal diagnosis.

In 2000, her research led to the discovery and development of the now patented ISET® technique for isolation and characterization of circulating tumor and fetal cells permitting predictive oncology and non invasive prenatal diagnosis. Prof Paterlini-Bréchot oversees the continuing development of the ISET® technology. Her work was acknowledged by numerous awards and led to high level scientific publications.

Dr. Hood Leroy
M.D., Johns Hopkins School of Medicine
Ph.D., Biochemistry, California Institute of Technology
Dr. Hood’s research has focused on the study of molecular immunology, biotechnology, and genomics.  He won the 2003 Lemelson-MIT Prize for inventing “four instruments that have unlocked much of the mystery of human biology” by helping decode the genome. His inventions include the DNA sequencer that contributed to the successful mapping of the human genome.

His professional career began at Caltech where he and his colleagues pioneered four instruments, which comprise the technological foundation for contemporary molecular biology. In 1992, Dr. Hood moved to the University of Washington as founder and Chairman of the cross-disciplinary Department of Molecular Biotechnology.

Joe Leigh Simpson
MD – Chair and Professor
Professor of Obstetrics and Gynecology
Professor of Human and Molecular Genetics
Dr Simpson is the founding Chair at Florida International University Miami, and has served as Chair and Professor in numerous universities in the USA. Besides, he has played leadership roles in many professional organizations. His research encompasses many areas of genetic prenatal diagnosis and reproductive genetics.

He was 1993-1994 President of the American Society for Reproductive Medicine, 1994-1998 President of the International Society of Prenatal Diagnosis, 1998-1999 President of the Society for Gynecologic Investigation, 2007-09 President of the American College of Medical Genetics, 2006-09 President of the Preimplantation Genetic Diagnosis International Society He is a member of the National Academy of Sciences, Institute of Medicine (IOM).

Frank Anthony Greco
MD
Dr. Tony Greco is board certified in Medical Oncology and Internal Medicine. He has been with Tennessee Oncology since 1993. Dr. Greco specializes in cancers of unknown primary, lung cancer, and germ cell tumors. Dr. Greco holds memberships in the American Society of Clinical Oncology and the Southern Association of Oncology.

He is also a clinical researcher and director of Sarah Cannon Cancer Center and co-director of the Minnie Pearl Research Network. Dr. Greco comes to us from Vanderbilt University Medical Center, where he served as the Director of Medical Oncology and the Cancer Center.

Jean-Yves Blay
MD, PhD
Dr. Jean-Yves Blay is Professor of Medicine at the Université Claude Bernard in Lyon, France, and the Scientific Director of the Canceropole Lyon Rhône Alpes, a network of more than 1500 researchers and physicians working in the field of cancer. He is President of the Executive Committee of the EORTC (European Organization for the Research and Treatment of Cancer), Chairman of the French Sarcoma Group, and Director in the Conticanet Network (Conticanet.eu), a Network of excellence funded by the 6th FrameWork Program of the European Commission.

His research interests focus on clinical and basic research in sarcomas, the biology of breast carcinoma and relation between tumor microenvironment and malignant cells. Dr. Blay is an active member of the European Society of Medical Oncology, the American Society of Clinical Oncology and the American Association of Cancer Research. Dr. Blay serves as scientific committee board member of five Cancer Centers in France.

Scroll to Top

You're one click away from your download !

It’s easy: all we need is your name, email & preferences to send you your brochure(s) !

You're one click away from your download !

It’s easy: all we need is your name, email & preferences to send you your brochure(s) !

You're one click away from your download !

It’s easy: all we need is your name, email & preferences to send you your brochure(s) !